Does the DRB1*1501 allele confer more severe and faster progression in primary progressive multiple sclerosis patients?. HLA in primary progressive multiple sclerosis

Journal of Neuroimmunology

Volumn 214, Issue 1-2, 2009, Pages 101-103

  Vasconcelos, Claudia Cristina Ferreira ^a,b   Fernández, Oscar ^c   Leyva, Laura ^c   Thuler, Luiz Claudio Santos ^a   Alvarenga, Regina Maria Papais ^a,b  

^a FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

^b HOSPITAL DA LAGOA   (Brazil)

^c Carlos Haya Teaching Hospital   (Spain)

Author keywords

Alleles; Genetic susceptibility; HLA; Multiple sclerosis; Primary progressive

Indexed keywords

HLA DQB1 ANTIGEN; HLA DR ANTIGEN; HLA DR2 ANTIGEN; DEVELOPMENTALLY REGULATED RNA BINDING PROTEIN 1, HUMAN; DEVELOPMENTALLY REGULATED RNA-BINDING PROTEIN 1, HUMAN; HLA DQ ANTIGEN; HLA DQB1 PROTEIN, HUMAN; HLA-DQB1 PROTEIN, HUMAN; MEMBRANE PROTEIN; NERVE PROTEIN; RNA BINDING PROTEIN;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HAPLOTYPE; HLA TYPING; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIPLE SCLEROSIS; PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS; PRIORITY JOURNAL; AFRICAN AMERICAN; CAUCASIAN; ETHNOLOGY; GENETICS; HOSPITALIZATION; IMMUNOLOGY; MIDDLE AGED;

ADULT; AFRICAN AMERICANS; ALLELES; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HAPLOTYPES; HLA-DQ ANTIGENS; HLA-DR2 ANTIGEN; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; NERVE TISSUE PROTEINS; RNA-BINDING PROTEINS; SEVERITY OF ILLNESS INDEX;

EID: 69949153061     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.06.009     Document Type: Article

References (30)

1. Alves-Leon S.V., Papais-Alvarenga R., Magalhães M., Alvarenga M., Thuler L.C., and Fernández y Fenández O. Ethnicity-dependent association of HLA DRB1-DQA1-DQB1 alleles in Brazilian multiple sclerosis patients. Acta Neurol. Scand. 115 (2007) 306-311
2. Barcellos L.F., Oksenberg J.R., Begovich A.B., Martin E.R., Schmidt S., Vittinghoff E., Goodin D.S., Pelletier D., Lincoln R.R., Bucher P., Swerdlin A., Pericak-Vance M.A., Haines J.L., Hauser S.L., and Multiple Sclerosis Genetics Group. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am. J. Hum. Genet. 72 (2003) 710-716
3. Barcellos L.F., Sawcer S., Ramsay P.P., Baranzini S.E., Thomson G., Briggs F., Cree B.C., Begovich A.B., Villoslada P., Montalban X., Uccelli A., Savettieri G., Lincoln R.R., DeLoa C., Haines J.L., Pericak-Vance M.A., Compston A., Hauser S.L., and Oksenberg J.R. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum. Mol. Genet. 15 (2006) 2813-2824
4. Caballero A., Alvés-León S., Papais-Alvarenga R., Fernández O., Navarro G., and Alonso A. DQB1*0602 confers genetic susceptibility to multiple sclerosis in Afro-Brazilians. Tissue Antigens 54 (1999) 524-526
5. de la Concha E.G., Arroyo R., Crusius J.B., Campillo J.A., Martin C., Varela de Seijas E., Peña A.S., Clavería L.E., and Fernandez-Arquero M. Combined effect of HLA-DRB1*1501 and interleukin-1 receptor antagonist gene allele 2 in susceptibility to relapsing/remitting multiple sclerosis. J. Neuroimmunol. 80 (1997) 172-178
6. DeLuca G.C., Ramagopalan S.V., Herrera B.M., Dyment D.A., Lincoln M.R., Montpetit A., Pugliatti M., Barnardo M.C., Risch N.J., Sadovnick A.D., Chao M., Sotgiu S., Hudson T.J., and Ebers G.C. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 20896-20901
7. Dyment D.A., Sadovnick A.D., and Ebers G.C. Genetics of multiple sclerosis. Hum. Mol. Genet. 6 (1997) 1693-1698
8. Fernández O., Fernández V., Alonso A., Caballero A., Luque G., Bravo M., León A., Mayorga C., Leyva L., and de Ramón E. DQB1*0602 allele shows a strong association with multiple sclerosis in patients in Malaga, Spain. J. Neurol. 251 (2004) 440-444
9. Francis D.A., Thompson A.J., Brookes P., Davey N., Lechler R.I., McDonald W.I., and Batchelor J.R. Multiple sclerosis and HLA: is the susceptibility gene really HLA-DR or -DQ?. Hum. Immunol. 32 (1991) 119-124
10. Hensiek A.E., Sawcer S.J., Feakes R., Deans J., Mander A., Akesson E., Roxburgh R., Coraddu F., Smith S., and Compston D.A. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 72 (2002) 184-187
11. Kantarci O.H., and Weinshenker B.G. Natural history of multiple sclerosis. Neurol. Clin. 23 (2005) 17-38
12. Kantarci O., and Wingerchuk D. Epidemiology and natural history of multiple sclerosis: new insights. Curr. Opin. Neurol. 19 (2006) 248-254
13. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
14. MacGregor A., Ollier W., Thomson W., Jawaheer D., and Silman A. HLA-DRB1*0401/0404 genotype and rheumatoid arthritis: increased association in men, young age at onset, and disease severity. J. Rheumatol. 22 (1995) 1032-1036
15. Masterman T., Ligers A., Olsson T., Andersson M., Olerup O., and Hillert J. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann. Neurol. 48 (2000) 211-219
16. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., and Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50 (2001) 121-127
17. Okuda D.T., Srinivasan R., Oksenberg J.R., Goodin D.S., Baranzini S.E., Beheshtian A., Waubant E., Zamvil S.S., Leppert D., Qualley P., Lincoln R., Gomez R., Caillier S., George M., Wang J., Nelson S.J., Cree B.A., Hauser S.L., and Pelletier D. Genotype-phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain 132 Pt 1 (2009) 250-259
18. Olerup O., and Hillert J. HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens 38 (1991) 1-15
19. Papais-Alvarenga R.M., Alves-Leon S.V., and Miranda Santos C.M. South Atlantic Project: a Brazilian multiple sclerosis trial. In: Arriaga R.C., and Nogales-Gaete J. (Eds). Esclerosis múltiple. Una mirada ibero-panamericana (2002), Arrynog-Ediciones, Santiago 129-154
20. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., Lublin F.D., Metz L.M., McFarland H.F., O'Connor P.W., Sandberg-Wollheim M., Thompson A.J., Weinshenker B.G., and Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 58 (2005) 840-846
21. Ramagopalan S.V., and Ebers G.C. Epistasis: multiple sclerosis and the major histocompatibility complex. Neurology 72 (2009) 566-567
22. Ramagopalan S.V., Deluca G.C., Degenhardt A., and Ebers G.C. The genetics of clinical outcome in multiple sclerosis. J. Neuroimmunol. 201-202 (2008) 183-199
23. Rasmussen H.B., Kelly M.A., and Clausen J. Additive effect the HLA-DR15 haplotype on susceptibility to multiple sclerosis. Mult. Scler. 7 (2001) 91-93
24. Runmarker B., Martinsson T., Wahlström J., and Andersen O. HLA and prognosis in multiple sclerosis. J. Neurol. 241 (1994) 385-390
25. Silva A.M., Pereira C., Bettencourt A., Carvalho C., Couto A.R., Leite M.I., Marta M., Freijo M., Costa P.P., Mendonça D., Monteiro L., Armas J.B., and Martins B. The role of HLA-DRB1 alleles on susceptibility and outcome of a Portuguese Multiple Sclerosis population. J. Neurol. Sci. 258 (2007) 69-74
26. Thompson A.J., Montalban X., Barkhof F., Brochet B., Filippi M., Miller D.H., Polman C.H., Stevenson V.L., and McDonald W.I. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann. Neurol. 47 (2000) 831-835
27. Weatherby S.J., Thomson W., Pepper L., Donn R., Worthington J., Mann C.L., Davies M.B., Fryer A.A., Boggild M.D., Young C.A., Jones P.W., Strange R.C., Ollier W.E., and Hawkins C.P. HLA-DRB1 and disease outcome in multiple sclerosis. J. Neurol. 248 (2001) 304-310
28. Weinshenker B.G., Bass B., Rice G.P., Noseworthy J., Carriere W., Baskerville J., and Ebers G.C. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112 (1989) 133-146
29. Weinshenker B.G., Santrach P., Bissonet A.S., McDonnell S.K., Schaid D., Moore S.B., and Rodriguez M. Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study. Neurology 51 (1998) 742-747
30. Willer C.J., Dyment D.A., Risch N.J., Sadovnick A.D., Ebers G.C., and Canadian Collaborative Study Group. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 12877-12882